Edition:
India

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.65USD
20 Jul 2018
Change (% chg)

$0.00 (+0.43%)
Prev Close
$0.65
Open
$0.64
Day's High
$0.66
Day's Low
$0.64
Volume
8,261
Avg. Vol
33,634
52-wk High
$2.83
52-wk Low
$0.61

Latest Key Developments (Source: Significant Developments)

Delmar Appoints Saiid Zarrabian Full-Time President And CEO
Tuesday, 22 May 2018 

May 22 (Reuters) - DelMar Pharmaceuticals Inc ::DELMAR APPOINTS SAIID ZARRABIAN TO FULL-TIME PRESIDENT AND CEO.DELMAR PHARMACEUTICALS - ZARRABIAN HAD PREVIOUSLY SERVED AS INTERIM PRESIDENT AND CEO SINCE NOVEMBER 2017.  Full Article

Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares
Saturday, 14 Apr 2018 

April 13 (Reuters) - DelMar Pharmaceuticals Inc ::TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES.  Full Article

Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14
Friday, 17 Nov 2017 

Nov 16 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing.  Full Article

Delmar Pharmaceuticals names Saiid Zarrabian interim CEO
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer.Jeffrey Bacha, cofounder of Co, will continue in role as president and in newly created position of chief operating officer​.Zarrabian and Bacha will continue to serve on company's board of directors​.  Full Article

DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - DelMar Pharmaceuticals Inc :DelMar Pharmaceuticals Inc <<>> CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing.  Full Article

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM